Impact of olmesartan on blood pressure, endothelial function, and cardiovascular outcomes

References

• FurchgottRFZawadzkiJVThe obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholineNature198028857893733766253831
   PubMed Web of Science ®Google Scholar
• DeanfieldJEHalcoxJPRabelinkTJEndothelial function and dysfunction: testing and clinical relevanceCirculation2007115101285129517353456
   PubMed Web of Science ®Google Scholar
• MunzelTSinningCPostFWarnholtzASchulzEPathophysiology, diagnosis and prognostic implications of endothelial dysfunctionAnn Med200840318019618382884
   PubMed Web of Science ®Google Scholar
• HalcoxJPSchenkeWHZalosGPrognostic value of coronary vascular endothelial dysfunctionCirculation2002106665365812163423
   PubMed Web of Science ®Google Scholar
• SpiekerLEluscherTFEndothelium in hypertension:nitric oxideOparilSWeberMHypertension: a Companion to Brenner and Rector’s The Kidney2nd edPhiladelphia, PAElsevier Saunders2005146158
   Google Scholar
• PalmerRMAshtonDSMoncadaSVascular endothelial cells synthesize nitric oxide from L-arginineNature198833361746646663131684
   PubMed Web of Science ®Google Scholar
• PalmerRMReesDDAshtonDSMoncadaSL-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxationBiochem Biophys Res Commun19881533125112563390182
   PubMed Web of Science ®Google Scholar
• HermannMFlammerALuscherTFNitric oxide in hypertensionJ Clin Hypertens (Greenwich)2006812 Suppl 4172917170603
   PubMedGoogle Scholar
• BrunnerHCockcroftJRDeanfieldJEndothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of HypertensionJ Hypertens200523223324615662207
   PubMed Web of Science ®Google Scholar
• FortePCoplandMSmithLMMilneESutherlandJBenjaminNBasal nitric oxide synthesis in essential hypertensionLancet199734990558378429121259
   PubMed Web of Science ®Google Scholar
• FeronODessyCDesagerJPBalligandJLHydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundanceCirculation2001103111311811136695
   PubMed Web of Science ®Google Scholar
• DeanfieldJDonaldAFerriCEndothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of HypertensionJ Hypertens200523171715643116
   PubMed Web of Science ®Google Scholar
• CelermajerDSSorensenKEGoochVMNon-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosisLancet19923408828111111151359209
   PubMed Web of Science ®Google Scholar
• LaurentSCockcroftJvan BortelLExpert consensus document on arterial stiffness: methodological issues and clinical applicationsEur Heart J200627212588260517000623
   PubMed Web of Science ®Google Scholar
• PimentaECalhounDAOparilSEtiology and pathogenesis of systemic hypertensionCrawfordMHDiMarcoJPPaulusWJCardiology3rd edPhiladelphia, PAElsevier2009511522
   Google Scholar
• O’RourkeMFHashimotoJMechanical factors in arterial aging: a clinical perspectiveJ Am Coll Cardiol200750111317601538
   PubMed Web of Science ®Google Scholar
• ChobanianAVAlexanderRWExacerbation of atherosclerosis by hypertension. Potential mechanisms and clinical implicationsArch Intern Med199615617195219568823148
   PubMedGoogle Scholar
• DzauVJAntmanEMBlackHRThe cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease)Circulation2006114252850287017179034
   PubMed Web of Science ®Google Scholar
• LinderLKiowskiWBuhlerFRLuscherTFIndirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertensionCirculation1990816176217672344673
   PubMed Web of Science ®Google Scholar
• PanzaJAQuyyumiAABrushJEJrEpsteinSEAbnormal endothelium-dependent vascular relaxation in patients with essential hypertensionN Engl J Med1990323122272355955
   PubMed Web of Science ®Google Scholar
• TaddeiSVirdisAMatteiPHypertension causes premature aging of endothelial function in humansHypertension19972937367439052889
   PubMed Web of Science ®Google Scholar
• EgashiraKSuzukiSHirookaYImpaired endothelium-dependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension. Different responses to acetylcholine and substance PHypertension19952522012067531175
   PubMed Web of Science ®Google Scholar
• StrawnWBChappellMCDeanRHKivlighnSFerrarioCMInhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemiaCirculation2000101131586159310747353
   PubMed Web of Science ®Google Scholar
• TaddeiSVirdisAMatteiPArzilliFSalvettiAEndothelium-dependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertensionJ Cardiovasc Pharmacol199220Suppl 12S193S1951282967
   PubMed Web of Science ®Google Scholar
• McAllisterASAtkinsonABJohnstonGDHaddenDRBellPMMcCanceDRBasal nitric oxide production is impaired in offspring of patients with essential hypertensionClin Sci (Lond)199997214114710409468
   PubMed Web of Science ®Google Scholar
• FerrarioCEffect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomilVasc Health Risk Manag20095130131419436655
   PubMedGoogle Scholar
• ImanishiTHanoTNishioIAngiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stressJ Hypertens20052319710415643130
   PubMed Web of Science ®Google Scholar
• HillJMZalosGHalcoxJPCirculating endothelial progenitor cells, vascular function, and cardiovascular riskN Engl J Med2003348759360012584367
   PubMed Web of Science ®Google Scholar
• VasaMFichtlschererSAicherANumber and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery diseaseCirc Res2001891E1E711440984
   PubMed Web of Science ®Google Scholar
• WassmannSCzechTvan EickelsMFlemingIBohmMNickenigGInhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout miceCirculation2004110193062306715277329
   PubMed Web of Science ®Google Scholar
• RuddyMCKostisJBAngiotensin II receptor antagonistsOparilSWeberMAHypertension: a Companion to Brenner and Rector’s The Kidney2nd edPhiladelphia, PAElsevier2005683704
   Google Scholar
• BrennerBMCooperMEde ZeeuwDEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med20013451286186911565518
   PubMed Web of Science ®Google Scholar
• PfefferMAMcMurrayJJVelazquezEJValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothN Engl J Med2003349201893190614610160
   PubMed Web of Science ®Google Scholar
• DahlofBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet20023599311995100311937178
   PubMed Web of Science ®Google Scholar
• LaeisPPuchlerKKirchWThe pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interactionJ Hypertens Suppl2001191S21S3211451211
   PubMedGoogle Scholar
• SchwochoLRMasonsonHNPharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjectsJ Clin Pharmacol200141551552711361048
   PubMed Web of Science ®Google Scholar
• MiuraSFujinoMHanzawaHMolecular mechanism underlying inverse agonist of angiotensin II type 1 receptorJ Biol Chem200628128192881929516690611
   PubMed Web of Science ®Google Scholar
• MiuraSKiyaYKanazawaTDifferential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive stateMol Endocrinol200822113914617901125
   PubMedGoogle Scholar
• NeutelJMClinical studies of CS-866, the newest angiotensin II receptor antagonistAm J Cardiol2001878A37C43C
   Web of Science ®Google Scholar
• OparilSSilfaniTNWalkerJFRole of angiotensin receptor blockers as monotherapy in reaching blood pressure goalsAm J Hypertens2005182 Pt 128729415752958
   PubMed Web of Science ®Google Scholar
• OparilSWilliamsDChrysantSGMarburyTCNeutelJComparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertensionJ Clin Hypertens (Greenwich)20013528329131811588406
   PubMedGoogle Scholar
• GilesTDOparilSSilfaniTNWangAWalkerJFComparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertensionJ Clin Hypertens (Greenwich)20079318719517341994
   PubMedGoogle Scholar
• BianchiSBigazziRCampeseVMMicroalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implicationsAm J Kidney Dis199934697399510585306
   PubMed Web of Science ®Google Scholar
• AdlerAIStevensRJManleySEBilousRWCullCAHolmanRRDevelopment and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)Kidney Int200363122523212472787
   PubMed Web of Science ®Google Scholar
• IrieFIsoHSairenchiTThe relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general populationKidney Int20066971264127116501489
   PubMed Web of Science ®Google Scholar
• TonelliMJosePCurhanGSacksFBraunwaldEPfefferMProteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trialBMJ20063327555142616714328
   PubMed Web of Science ®Google Scholar
• RuilopeLIzzoJHallerHPrevention of microalbuminuria in patients with type 2 diabetes: what do we know?J Clin Hypertens (Greenwich)201012642243020591087
   PubMed Web of Science ®Google Scholar
• HallerHVibertiGCMimranAPreventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) studyJ Hypertens200624240340816508590
   PubMed Web of Science ®Google Scholar
• HallerHItoSIzzoJLJrPrevention of microalbuminuria in type 2 diabetes (ROADMAP Trial)J Hypertens201028Suppl Ae233
   Web of Science ®Google Scholar
• FliserDBuchholzKHallerHAntiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammationCirculation200411091103110715313950
   PubMed Web of Science ®Google Scholar
• SmithRDYokoyamaHAverillDBThe protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristicsAm J Cardiovasc Drugs20066533534217083268
   PubMedGoogle Scholar
• SmithRDYokoyamaHAverillDBSchiffrinELFerrarioCMReversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptorsJ Am Soc Hypertens20082316517220409899
   PubMed Web of Science ®Google Scholar
• NayaMTsukamotoTMoritaKOlmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patientsJ Am Coll Cardiol200750121144114917868805
   PubMed Web of Science ®Google Scholar
• StumpeKOAgabiti-RoseiEZielinskiTCarotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) studyTher Adv Cardiovasc Dis2007129710619124398
   PubMedGoogle Scholar
• HirohataAYamamotoKMiyoshiTImpact of olmesartan on progression of coronary atherosclerosis: a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trialJ Am Coll Cardiol2010551097698220202514
   PubMed Web of Science ®Google Scholar
• PimentaEOparilSFixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combinationVasc Health Risk Manag20084365366418827915
   PubMedGoogle Scholar